中国肺癌杂志2025，Vol.28Issue(10)：787-797,11.DOI:10.3779/j.issn.1009-3419.2025.101.18
IL-6在非小细胞肺癌患者筛查与预后中的研究进展
Research Progress on Interleukin-6 in Screening and Prognosis of Patients with Non-small Cell Lung Cancer
摘要
Abstract
Non-small cell lung cancer(NSCLC),the predominant histological subtype of lung cancer,mandates precise screening and accurate prognostic assessment to guide therapeutic strategies and improve patient survival.The initia-tion and progression of NSCLC are intimately linked to inflammatory responses.Interleukin-6(IL-6),a pivotal inflammatory mediator,critically modulates the tumor microenvironment,immune evasion,tumor progression,and therapy resistance in NSCLC.Recent evidence indicates that IL-6 not only participates in the biological behavior of NSCLC but also holds promise as a potential biomarker for early detection and prognostication.This review summarizes the role of IL-6 in NSCLC screening,treatment-related adverse events,and its utility in the management of NSCLC-associated comorbidities.关键词
肺肿瘤/白细胞介素-6/预后/筛查Key words
Lung neoplasms/Interleukin-6/Prognosis/Screening引用本文复制引用
Dongyang XU,Chenxiao QIAO,Xiaoying ZHANG,Qingchao KONG,Xiang JI..IL-6在非小细胞肺癌患者筛查与预后中的研究进展[J].中国肺癌杂志,2025,28(10):787-797,11.基金项目
This paper was supported by the grant from Clinical Special Research Fund of Shandong Medical Association(No.YX-H2022ZX02027)(to Xiang JI). 本文受山东省医学会临床专项科研基金(No.YXH2022ZX02027)资助 （No.YX-H2022ZX02027）
